In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canary in the Coalmine: Pfizer R&D

Executive Summary

In an interview, Pfizer's head of R&D, John LaMattina, discusses R&D's position as the part of the company most vulnerable to cuts in response to weakening sales. Among other issues, LaMattina discusses Pfizer's increasing interest in large molecules, specialist markets and combination products, and the role external research will play in filling a pipeline facing significant near-term generic pressures. He also details Pfizer's advantages of scale, particularly in developing portfolios of products in individual disease areas for sale to major customers interested in large discounted, disease-managed product packages.
Advertisement

Related Content

Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
Pfizer's Change Management: Unfamiliar Faces
Torcetrapib: Biomarker for the Big Pharma Business Model
The Winners Post-Vioxx: Merck's Product-Focused Biotechs
Combination Drugs
Clinical Trials, Corporate Transparency
Big Pharma's Large Molecule Challenge
Pfizer R&D: The Biggest Pharmaceutical Experiment
Pfizer's Balancing Act
Pfizer: Innovation at the Lowest Cost

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel